Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5031351 | 0.93 | — | — | |
| SCHEMBL13996165 | 0.85 | KMT2A (0.33) | SMN1; SMN2 | |
| SCHEMBL5034598 | 0.81 | PKM (0.32) | — | |
| SCHEMBL13527454 | 0.80 | — | — | |
| SCHEMBL4540777 | 0.75 | POLB (0.33) | — | |
| SCHEMBL5031317 | 0.75 | — | — | |
| SCHEMBL5031360 | 0.75 | PKM (0.31) | — | |
| SCHEMBL5030440 | 0.63 | TLR7 (0.36) | — | |
| SCHEMBL5034602 | 0.60 | — | — | |
| SCHEMBL25353226 | 0.54 | CYP2D6 (0.39) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312434-A1 | PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20050032829-A1 | Process for imidazo[4,5-c]pyridin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312434-A1 | PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES | PAICS, HTR4, PNPO | SMN1; SMN2 824/4885 |
| US-20050032829-A1 | Process for imidazo[4,5-c]pyridin-4-amines | PAICS, HTR4, PNPO | SMN1; SMN2 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.